Today The Pfizer’s (PFE) Hold Rating Reaffirmed at Jefferies Group LLC

Today The Pfizer’s (PFE) Hold Rating Reaffirmed at Jefferies Group LLC

Jefferies Group LLC reissued their hold rating on shares of Pfizer, Inc. (NYSE:PFE) in a report issued on Thursday. They currently have a $30.00 price objective on the biopharmaceutical company’s stock.

“We wanted to highlight a key data catalyst in which a positive outcome can drive shares higher: PIIa data for XEN801 for mod-to-severe acne in the latter part of Q1 (JEF est: ~Mar). We continue to like the risk/reward going into the data, especially on the heels of Dermira’s positive PIIb data for DRM01, which operates on the same pathway but more upstream. Reiterating Buy and $13 PT. Highlighting Key PIIa Data Catalyst in Latter Part of Q1: We wanted to take the opportunity to highlight a key data catalyst in which a positive outcome can drive shares higher: topline PIIa data catalyst for XEN801 for moderate-to-severe acne in the latter part of Q1 (JEF estimate: ~Mar). We previously conducted a review on XEN801 in April ’16, which can be found here, and now that the data catalyst is drawing near, we wanted to take the chance to highlight it again. To recap, the PIIa trial is a randomized, double- blind, multicentre, vehicle-controlled trial evaluating the efficacy and safety of patients with moderate-to-severe acne. The trial will compare XEN801 topical gel (1%) and matching placebo gel for 12 weeks with a 4-week follow-up. XENE has randomized 165 patients (v. 150 that was planned at conception), and has 85% power (v. 80% previously) to detect a ~16% difference.”,” Jefferies Group LLC’s analyst commented.

A number of other brokerages have also recently issued reports on PFE. Guggenheim initiated coverage on Pfizer in a report on Friday, December 2nd. They set a neutral rating on the stock. Zacks Investment Research upgraded Pfizer from a hold rating to a buy rating and set a $36.00 target price on the stock in a report on Tuesday, January 3rd. Bank of America Corporation restated a buy rating and set a $40.00 target price on shares of Pfizer in a report on Tuesday, September 27th. Vetr cut Pfizer from a strong-buy rating to a buy rating and set a $36.36 target price on the stock. in a report on Thursday, October 13th. Finally, Argus restated a buy rating and set a $39.00 target price on shares of Pfizer in a report on Tuesday, October 4th. Thirteen equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer currently has an average rating of Buy and a consensus target price of $37.07.

Shares of Pfizer (NYSE:PFE) traded up 0.080% during midday trading on Thursday, hitting $31.175. The company had a trading volume of 4,344,084 shares. The firm’s 50-day moving average is $32.43 and its 200-day moving average is $33.52. Pfizer has a 12-month low of $28.25 and a 12-month high of $37.39. The firm has a market capitalization of $189.18 billion, a P/E ratio of 31.300 and a beta of 0.91.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by $0.01. The firm earned $13.05 billion during the quarter, compared to the consensus estimate of $13.05 billion. Pfizer had a net margin of 13.09% and a return on equity of 23.68%. Pfizer’s revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.60 EPS. On average, analysts predict that Pfizer will post $2.41 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, February 3rd will be given a dividend of $0.32 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.30. The ex-dividend date is Wednesday, February 1st. This represents a $1.28 annualized dividend and a dividend yield of 4.11%. Pfizer’s payout ratio is 106.20%.

In other Pfizer news, insider Anthony J. Maddaluna sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $33.00, for a total transaction of $330,000.00. Following the transaction, the insider now owns 112,087 shares of the company’s stock, valued at approximately $3,698,871. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Albert Bourla sold 18,390 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $30.05, for a total value of $552,619.50. Following the transaction, the insider now directly owns 149,199 shares in the company, valued at approximately $4,483,429.95. The disclosure for this sale can be found here. 0.07% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of The West increased its position in shares of Pfizer by 28.0% in the third quarter. Bank of The West now owns 157,475 shares of the biopharmaceutical company’s stock valued at $5,334,000 after buying an additional 34,415 shares in the last quarter. Seaward Management Limited Partnership increased its position in shares of Pfizer by 5.7% in the second quarter. Seaward Management Limited Partnership now owns 908,421 shares of the biopharmaceutical company’s stock valued at $31,985,000 after buying an additional 48,827 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Pfizer by 24.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 1,427,125 shares of the biopharmaceutical company’s stock valued at $48,337,000 after buying an additional 280,987 shares in the last quarter. State of Alaska Department of Revenue increased its position in shares of Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock valued at $13,093,000 after buying an additional 37,647 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in shares of Pfizer by 0.4% in the third quarter. Fisher Asset Management LLC now owns 31,836,368 shares of the biopharmaceutical company’s stock valued at $1,078,298,000 after buying an additional 111,838 shares in the last quarter. 69.51% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. The Company’s segments include Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). Its biopharmaceutical products include Lipitor, Sutent and the Premarin family of products.

Related posts

Leave a Comment